Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1066805 | 0.88 | ALDH1A1 (0.41) | ALDH1A1CYP1A2MAPTCYP2D6CYP3A4 | |
| SCHEMBL14010813 | 0.84 | — | — | |
| SCHEMBL8402970 | 0.84 | ALDH1A1 (0.51) | ALDH1A1CYP1A2MAPTCYP2D6CYP3A4 | |
| SCHEMBL1292809 | 0.83 | NAMPT (0.44) | ALDH1A1CYP1A2MAPTKMT2APOLB | |
| SCHEMBL944668 | 0.80 | ALDH1A1 (0.53) | ALDH1A1CYP1A2MAPTTSHRHPGD | |
| SCHEMBL11406691 | 0.80 | — | — | |
| SCHEMBL2387242 | 0.80 | HPGD (0.44) | ALDH1A1CYP3A4USP2HSD17B10HPGD | |
| SCHEMBL23210747 | 0.78 | — | — | |
| SCHEMBL1220310 | 0.78 | KMT2A (0.52) | ALDH1A1MAPTHPGDSMN1; SMN2KMT2A | |
| SCHEMBL13450960 | 0.78 | KMT2A (0.52) | ALDH1A1MAPTHPGDSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-06-20 | — | — | US | claimed |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2024-05-30 | — | — | US | claimed |
| EP-4355741-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Biotheryx, Inc. (US) | 2024-04-24 | — | — | EP | claimed |
| WO-2022266248-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| EP-2240506-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2012-12-26 | — | — | EP | claimed |
| US-8247557-B2 | IAP inhibitors | GENENTECH, INC. (US) | 2012-08-21 | — | — | US | claimed |
| US-20120015974-A1 | IMIDAZOPYRIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-01-19 | — | — | US | claimed |
| JP-2012500272-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-8063218-B2 | Imidazopyridine inhibitors of IAP | GENENTECH, INC. (US) | 2011-11-22 | — | — | US | claimed |
| US-20110218211-A1 | AZAINDOLE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2011-09-08 | — | — | US | claimed |
| EP-2148858-A1 | INHIBITORS OF IAP | Genentech, Inc. (US) | 2010-02-03 | — | — | EP | claimed |
| EP-2125809-A1 | IMIDAZOPYRIDINE INHIBITORS OF IAP | Genentech, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| US-20090221630-A1 | IAP INHIBITORS | GENENTECH, INC. | 2009-09-03 | — | — | US | claimed |
| WO-2009089502-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2009-07-16 | — | — | WO | claimed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | claimed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | claimed |
| WO-2008134679-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2008-11-06 | — | — | WO | claimed |
| EP-1973899-A2 | INHIBITORS OF IAP | Genentech, Inc. (US) | 2008-10-01 | — | — | EP | claimed |
| WO-2008079735-A1 | IMIDAZOPYRIDINE INHIBITORS OF IAP | GENENTECH, INC. (US) | 2008-07-03 | — | — | WO | claimed |
| WO-2007106192-A2 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2007-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221630-A1 | IAP INHIBITORS | XIAP, BIRC5, BIRC3 | ALDH1A1 4440/4885CYP1A2 4745/4885MAPT 2631/4885 |
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | ALDH1A1 3564/4885CYP1A2 2874/4885MAPT 989/4885 |
| US-20120015974-A1 | IMIDAZOPYRIDINE INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | ALDH1A1 4176/4885CYP1A2 4743/4885MAPT 3159/4885 |
| US-20110218211-A1 | AZAINDOLE INHIBITORS OF IAP | XIAP, BIRC5, API5 | ALDH1A1 3906/4885CYP1A2 4505/4885MAPT 3981/4885 |
| US-20240174643-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | ALDH1A1 3542/4885CYP1A2 2856/4885MAPT 971/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | ALDH1A1 802/4885CYP1A2 337/4885MAPT 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.